{
    "clinical_study": {
        "@rank": "38412", 
        "arm_group": {
            "arm_group_label": "Group 1"
        }, 
        "brief_summary": {
            "textblock": "The objective of the study is to investigate and collect post marketing data on the safety\n      and efficacy of Visanne at follow-up visit after about 6 months of treatment and - for a\n      subset of patients - at optional long-term follow-up visit after about 1 year of treatment\n      under daily practice treatment conditions in Korean women and to obtain data on drug\n      utilization on treatment for endometriosis."
        }, 
        "brief_title": "Regulatory Post Marketing Surveillance Study in Korea", 
        "completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Endometriosis", 
        "condition_browse": {
            "mesh_term": "Endometriosis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed and dated informed consent\n\n          -  Women diagnosed by a physician as having endometriosis\n\n          -  Women who are prescribed Visanne(dienogest 2mg)for the first time during the study\n             period\n\n        Exclusion Criteria:\n\n        - All contraindications according to the local marketing authorization have to be\n        considered."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Women desiring treatment for endometriosis using Visanne (dienogest 2mg)"
            }
        }, 
        "enrollment": {
            "#text": "3750", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01788722", 
            "org_study_id": "16625", 
            "secondary_id": "VS1310KR"
        }, 
        "intervention": {
            "arm_group_label": "Group 1", 
            "description": "Patients in daily life clinical practice tratment receiving Visanne (dienogest 2mg) according to indication on the label.", 
            "intervention_name": "Visanne (Dienogest, BAY86-5258)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Dienogest"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 3, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many Locations", 
                    "country": "Korea, Republic of"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "1", 
        "official_title": "Visanne\u00ae (Dienogest 2mg) Regulatory Post Marketing Surveillance Study in Korea", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea : Korea Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants with adverse events( AE) and Serious adverse events(SAE) as a measure of safety and tolorability", 
            "safety_issue": "Yes", 
            "time_frame": "up to 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01788722"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Changes of relief of endometriosis-associated pelvic pain (EAPP) will be measured on VAS for total study population", 
                "safety_issue": "No", 
                "time_frame": "6 months and 1 year"
            }, 
            {
                "measure": "Evaluation of VAS score changes for sub analysis( In case of VAS score\u2265 30mm in initial visit).", 
                "safety_issue": "No", 
                "time_frame": "6 months and 1 year"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "June 2014"
    }
}